Digestery
Longevity supplements › Metformin and Aging › Studies

Animal study

In mice given a drug that speeds aging signs, metformin countered some aging markers

Sun and colleagues · Experimental gerontology · 2022

Original title: Characterization of cellular senescence in doxorubicin-induced aging mice.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Some markers of senescent cells (p21WAF1/CIP1, p16INK4A, and γH2AX) were upregulated by doxorubicin and then counteracted by metformin treatment.

The study at a glance

Type of study
Animal study
Who or what was studied
Mice given the drug doxorubicin to speed up aging signs
What was tested
Doxorubicin 5 mg/kg to induce aging markers, then metformin treatment
What it measured
Lab tests or markers
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Experimental gerontology, 2022
Source
PubMed record 35398171. This page is based on the abstract only.

How much this study counts

  • –Done in animals. Results in animals often do not carry over to people.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

    ↑ This study is the ringed dot

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 2 papers on the same step: 1 benefit, 1 harm. This one found benefit.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.